Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Moderna, Inc. (NASDAQ:MRNA)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on October 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Moderna Stock Performance

Shares of MRNA stock opened at $248.69 on Thursday. The stock has a market capitalization of $100.63 billion, a price-to-earnings ratio of -35.03 and a beta of 1.16. Moderna, Inc. has a one year low of $22.28 and a one year high of $280.80. The company’s 50-day simple moving average is $198.57 and its 200-day simple moving average is $94.60. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. During the same period in the previous year, the company earned ($0.51) earnings per share. Moderna’s quarterly revenue was up 29.2% on a year-over-year basis. Equities analysts anticipate that Moderna, Inc. will post -5.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 39,145 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the completion of the transaction, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. This represents a 2.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 197,251 shares of company stock valued at $33,875,904 in the last quarter. Company insiders own 10.80% of the company’s stock.

Moderna News Summary

Here’s some of the latest news about MRNA:

• Positive Sentiment: A real-world study of more than 294,000 U.S. veterans aged 65 and older reported comparative-effectiveness data for mNEXSPIKE. The findings may strengthen evidence for the vaccine in an older-adult market. Moderna announces mNEXSPIKE real-world data publication
• Positive Sentiment: Goldman Sachs reportedly sees potential for substantial share-price appreciation, while Brookline Capital Markets raised its FY2026–FY2028 EPS estimates, though the company is still expected to post losses in those years. Goldman Sachs forecast for Moderna shares
• Neutral Sentiment: CEO Stéphane Bancel described efforts to build a commercial case for a cancer vaccine that could eventually compete with Keytruda. This signals pipeline ambition, but the report does not describe a near-term product launch or confirmed sales outlook. Moderna CEO discusses cancer vaccine ambitions

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research reports. Berenberg Bank lifted their target price on Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research report on Friday, September 11th. Argus raised Moderna from a “hold” rating to a “buy” rating and set a $180.00 price target on the stock in a research report on Friday, August 28th. Citigroup reissued a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. TD Cowen restated a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Finally, Bank of America lifted their price objective on shares of Moderna from $170.00 to $200.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $113.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRNA. BlackRock Inc. bought a new stake in Moderna in the second quarter valued at $2,142,877,000. Theleme Partners LLP bought a new position in shares of Moderna during the second quarter worth about $564,272,000. Merck & Co. Inc. bought a new position in shares of Moderna during the second quarter worth about $161,642,545. Bamco Inc. NY bought a new position in shares of Moderna during the second quarter worth about $139,317,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Moderna in the 2nd quarter worth about $119,168,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Moderna Company Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.